Moody Aldrich Partners’s Crinetics Pharmaceuticals CRNX Stock Holding History

Moody Aldrich Partners’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.47M	Sell	146,077 -37,361	-20%	-$1.39M	0.98%	36
2026 Q1	$6.66M	Buy	183,438 +73,023	+66%	+$3.26M	1.2%	16
2025 Q4	$5.14M	Sell	110,415 -5,128	-4%	-$228K	0.96%	33
2025 Q3	$4.81M	Sell	115,543 -22,253	-16%	-$712K	0.91%	40
2025 Q2	$3.96M	Sell	137,796 -2,109	-2%	-$65.1K	0.77%	63
2025 Q1	$4.69M	Sell	139,905 -4,461	-3%	-$167K	0.98%	38
2024 Q4	$7.38M	Buy	144,366 +5,236	+4%	+$293K	1.37%	16
2024 Q3	$7.11M	Sell	139,130 -11,053	-7%	-$570K	1.29%	23
2024 Q2	$6.73M	Buy	150,183 +93,781	+166%	+$4.33M	1.31%	16
2024 Q1	$2.64M	Buy	+56,402	New	+$2.21M	0.45%	82
2023 Q4	–	Sell	-61,979	Closed	-$1.84M	–	202
2023 Q3	$1.84M	Buy	+61,979	New	+$1.28M	0.35%	91

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moody Aldrich Partners's CRNX Position: Q2 2026 in Review

Moody Aldrich Partners reduced its Crinetics Pharmaceuticals (CRNX) stake by 20% in Q2 2026, selling an estimated $1.39M and leaving 146,077 shares worth $5.47M. The position accounts for 0.98% of the portfolio, ranked #36.

Moody Aldrich Partners first reported a position in CRNX in Q3 2023 and has held it in 11 quarters since. The position peaked at $7.38M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Moody Aldrich Partners held 146,077 shares of Crinetics Pharmaceuticals worth $5.47M as of Q2 2026.
Moody Aldrich Partners sold 37,361 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.39M.
Crinetics Pharmaceuticals made up 0.98% of Moody Aldrich Partners's portfolio in Q2 2026, its #36 holding.
Moody Aldrich Partners first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Moody Aldrich Partners's Crinetics Pharmaceuticals position peaked at $7.38M in Q4 2024.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.